Answers are grounded in this paper and cite their sources.
Parkinson’s disease (PD) is a progressive neurodegenerative disorder, yet reliable and minimally invasive biomarkers for accurate diagnosis and clinical stratification remain lacking. Here, we aimed to identify plasma-based protein biomarkers with diagnostic and differential utility for PD. Plasma samples from 391 participants were analyzed using a two-stage design. In the discovery phase, label-free quantitative proteomics identified differentially expressed proteins between patients with PD and healthy controls, followed by functional enrichment analyses. A machine learning–based feature selection strategy was used to derive candidate biomarker panels. In the validation phase, selected proteins were quantified by enzyme-linked immunosorbent assay in an independent cohort including patients with PD, patients with multiple system atrophy, Parkinsonian type (MSA-P), and healthy controls. Diagnostic performance was evaluated using receiver operating characteristic analyses, and associations with clinical features were examined. Proteomic profiling identified 121 differentially expressed proteins related to vesicle trafficking, oxidative stress, and autophagy. A plasma protein panel comprising LAMP1, APOD, VIM, CTSF, and HEG1 showed robust performance in distinguishing PD from healthy controls, while a simplified combination moderately differentiated PD from MSA-P. Selected biomarkers were also associated with clinical scales of cognition and non-motor symptoms, supporting the potential utility in the clinical assessment of PD.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: